MedTrace Logo

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

NCT04159974 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-05-09

No results posted yet for this study

Summary

A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition

Conditions

  • Esophageal Adenocarcinoma

Interventions

DRUG

Durvalumab 50 MG/ML

IV Infusion

DRUG

Tremelimumab

IV Infusion, Combination with Durvalumab

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Cologne

    lead OTHER

Principal Investigators

  • Thomas Zander, Prof. Dr. med · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159974 on ClinicalTrials.gov